Dipeptidyl peptidase 1 inhibitors and neutrophilic inflammation in bronchiectasis: a narrative review.

Background And Objective: Bronchiectasis is a chronic respiratory disease characterized by predominantly neutrophilic inflammation, recurrent infection and pathological dilatation of the airways. Current therapeutic strategies primarily target infections and improving mucus clearance. However, no current treatment can directly ameliorate neutrophilic inflammation.

Autologous transplantation of lung progenitor cells comes into reality for bronchiectasis.

Stem and progenitor cell-based regenerative therapies have the potential to cure chronic respiratory diseases. Yan et al. reported a clinical trial of autologous P63 progenitor cell transplantation in bronchiectasis patients, highlighting autologous transplantation of P63 progenitor cells as a novel candidate therapeutic option to improve pulmonary gas exchange function and quality of life.

Clinical Characteristics and Outcomes of the Phenotypes of COPD-Bronchiectasis Association.

Introduction: Although COPD may frequently co-exist with bronchiectasis [COPD-bronchiectasis associated (CBA)], little is known regarding the clinical heterogeneity. We aimed to identify the phenotypes and compare the clinical characteristics and prognosis of CBA.

Methods: We conducted a retrospective cohort study involving 2928 bronchiectasis patients, 5158 COPD patients, and 1219 patients with CBA hospitalized between July 2017 and December 2020.